Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00197613 | The Adult Antiretroviral Treatment and Resistance Study (Tshepo) | PHASE3 | COMPLETED | 650 | — | — | Dec 1, 2002 | Dec 1, 2007 | Sep 17, 2012 | 1 | Botswana |
| Name | Type | Description |
|---|---|---|
| (A) zidovudine, lamivudine and nevirapine | DRUG | - |
| (B) zidovudine, lamivudine and efavirenz | DRUG | - |
| (C) zidovudine, didanosine, and nevirapine | DRUG | - |
| (D) zidovudine, didanosine, and efavirenz | DRUG | - |
| (E) stavudine, lamivudine, and nevirapine | DRUG | - |
| (F) stavudine, lamivudine and efavirenz | DRUG | - |
| Adherence Strategy Standard of Care (SOC) | PROCEDURE | - |
| Adherence Strategy Community-Based DOT | PROCEDURE | - |
Inclusion Criteria:(1) HIV infection indicated by (a) positive ELISA in two separate blood samples, the second no more than eight weeks prior to randomization), (b) CD4 cell count of less than 200 cells/ml OR CD4 cell count between 201-350 with plasma HIV-1 RNA level of greater than 55,000 copies/ml...